APG222 / AbbVie - LARVOL DELTA

Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results (GlobeNewswire) - "APG990 program progressing as a differentiated OX40L-targeted opportunity....Apogee expects to select a development candidate for its APG990 program in 2024. APG222 program advancing with a dual mechanism targeting both IL-13 and OX40L: APG222 is one or more SQ extended half-life mAbs targeting both IL-13 and OX40L, for the potential treatment of AD and other I&I indications. By blocking OX40L and IL-13, APG222 could simultaneously decrease OX40L signaling, helping to rebalance the immune system and decrease immune cell differentiation and cytokine release, and further reduce IL-13, resulting in even less immune signaling. This approach has the potential to prevent certain disease-related signs and symptoms that are driven by IL-13 signaling and the downstream inflammatory cascade."

Pipeline update • Preclinical • Atopic Dermatitis • Immunology